Multigene-engineered fibroblast-derived biomimetic vesicles for cancer multimodal targeting and immune reprogramming
In the authors' words
Despite advances of biomimetic vesicles in cancer therapy, clinical challenges such as biosafety, scalability, and therapeutic efficacy remain significant hurdles. To address these limitations, we reveal the critical tumor-homing motifs of cancer cell membrane vesicles: a synergistic “chemotactic recruitment-adhesion anchoring” cascade effect, especially chemokine axes (e.g., CXCL12/CXCR4) and integrins (e.g., αVβ3). In this study, we identify autologous fibroblasts as an ideal “chassis” cell for engineering biomimetic carriers. Using this platform, we construct multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing critical chemokine receptor CXCR4 and adhesion ligand iRGD, as well as PD-1 and CD47 protein, which achieved robust and broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models. Significantly, CD47-modified X-Fb-MNVs reduced hepatic accumulation and phagocytic clearance, thereby minimizing off-target effects in vivo and improving tumor targeting efficiency. By loading diABZI STING agonist into X-Fb-MNVs with overexpressed PD-1, our system activates both T cell and innate immunity, reversing ICB resistance and achieving 83.3% survival with no tumor recurrence and long-term immune surveillance over 90 d, whereas no mice survived with free diABZI treatment. By merging multimodal targeting, immune reprogramming, and scalable production into a single platform, X-Fb-MNVs represent a remarkable biomimetic system with transformative potential for a wide-spectrum cancer immunotherapy.
Appeared: Thursday, November 19. Proceedings of the National Academy of Sciences. Peer-reviewed journal.